@article{17f6400a634742fd8554b94b9fa66fba,
title = "Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies",
abstract = "Objective: To determine the association between the focal atrophy measures on antemortem MRI and postmortem neuropathologic classification of dementia with Lewy bodies (DLB) using the Third Report of the DLB Consortium criteria. Methods: We retrospectively identified 56 subjects who underwent antemortem MRI and had Lewy body (LB) pathology at autopsy. Subjects were pathologically classified as high (n = 25), intermediate (n = 22), and low likelihood DLB (n = 9) according to the Third Report of the DLB Consortium criteria. We included 2 additional pathologic comparison groups without LBs: one with low likelihood Alzheimer disease (AD) (control; n = 27) and one with high likelihood AD (n = 33). The associations between MRI-based volumetric measurements and the pathologic classification of DLB were tested with analysis of covariance by adjusting for age, sex, and MRI-to-death interval. Results: Antemortem hippocampal and amygdalar volumes increased from low to intermediate to high likelihood DLB (p < 0.001, trend test). Smaller hippocampal and amygdalar volumes were associated with higher Braak neurofibrillary tangle stage (p < 0.001). Antemortem dorsal mesopontine gray matter (GM) atrophy was found in those with high likelihood DLB compared with normal control subjects (p = 0.004) and those with AD (p = 0.01). Dorsal mesopontine GM volume decreased from low to intermediate to high likelihood DLB (p = 0.01, trend test). Conclusion: Antemortem hippocampal and amygdalar volumes increase and dorsal mesopontine GM volumes decrease in patients with low to high likelihood DLB according to the Third Report of the DLB Consortium criteria. Patients with high likelihood DLB typically have normal hippocampal volumes but have atrophy in the dorsal mesopontine GM nuclei.",
author = "Kejal Kantarci and Ferman, {Tanis J.} and Boeve, {Bradley F.} and Weigand, {Stephen D.} and Scott Przybelski and Prashanthi Vemuri and Murray, {Melissa M.} and Senjem, {Matthew L.} and Smith, {Glenn E.} and Knopman, {David S.} and Petersen, {Ronald C.} and Jack, {Clifford R.} and Parisi, {Joseph E.} and Dickson, {Dennis W.}",
note = "Funding Information: K. Kantarci is funded by the NIH (R01-AG040042 [PI], R21-NS066147 [PI] , Mayo Clinic Alzheimer's Disease Research Center/Project 1-P50-AG16574/P1 [PI], and R01-AG11378 [Co-I]). T. Ferman is funded by the NIH [Mayo Clinic Alzheimer's Disease Research Center/Project 1-P50-AG16574/P1 [Co-I]) . B. Boeve has served as an investigator for a clinical trial sponsored by Cephalon, Inc. He has received honoraria from the American Academy of Neurology. He receives research support from the National Institute on Aging (P50-AG16574 [Co-I], U01 AG06786 [Co-I], R01-AG15866 [Co-I], and U24-AG26395 [Co-I]) , and the Alzheimer's Association (IIRG-05–14560 [PI]). S. Weigand and S. Przybelski report no disclosures. P. Vemuri is funded by the NIH (K99-AG037573) . M. Murray and M. Senjem report no disclosures. G. Smith is funded by the NIH (P50-AG16574). D. Knopman serves as an Associate Editor for Neurology {\textregistered}; serves on a data safety monitoring board for Lilly Pharmaceuticals; is an investigator in a clinical trial sponsored by Baxter, Elan Pharmaceuticals and Forest Pharmaceuticals; and receives research support from the NIH (R01-AG11378 [Co-I], P50-AG16574 [Co-I], U01-AG 06786 [Co-I], AG29550 [Co-I], AG32306 [Co-I], and U01–96917 [Co-I]). R. Petersen serves on scientific advisory boards for Elan Pharmaceuticals, Wyeth Pharmaceuticals, and GE Healthcare and receives research support from the NIH (P50-AG16574 [PI] and U01-AG06786 [PI], R01-AG11378 [Co-I], and U01–24904 [Co-I]). C. Jack serves as a consultant for Elan Corporation and receives research support from Pfizer, Inc, the NIA (AG11378 [PI], P50-AG16574 [Co-I], and U01-AG024904–01 [Co-I]), and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation. J. Parisi is funded by the NIH (P50-AG16574/Neuropathology Core [Co-PI]). D. Dickson is funded by the NIH (P50-AG16574/Neuropathology Core [PI], P01-AG017216 [PI], P50-NS072187 [PI], and R01-AG040042 [Co-I]). Go to Neurology.org for full disclosures. ",
year = "2012",
month = aug,
day = "7",
doi = "10.1212/WNL.0b013e31826357a5",
language = "English (US)",
volume = "79",
pages = "553--560",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "6",
}